Related Experiment Video
Updated: Jun 13, 2026
Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
Published on: July 25, 2020
[Targeted therapies: sequential and combined treatments]
1Institut Gustave-Roussy, 114, rue Edouard-Vaillant, 94805, Villejuif, France. marine.grossgoupil@igr.fr
Abstract:
The treatment of metastatic kidney cancer has dramatically changed in the last three years, with demonstration of efficacy of sunitinib, sorafenib, temsirolimus, bevacizumab combined with interferon and more recently everolimus. Although the international guidelines have recently been reviewed, some major questions are still open. Particularly, the best order of administration of these targeted therapies should be considered, since sequential schedule becomes usual with the availability of these new agents. At the same time, the tolerability and efficacy of the combination of the targeted therapies are under investigation in clinical trials. We report recent studies, mainly presented during the ASCO 2007 and 2008 congress. Furthermore, other studies are ongoing to answer other important questions, to optimize the treatment of this disease, such as the role of nephrectomy in case of synchronous metastatic disease, or the efficacy of the targeted therapies in different histological subtype than clear cell carcinoma, or in neoadjuvant and adjuvant settings.
Insights
Recent advancements in metastatic kidney cancer treatment include targeted therapies like sunitinib and everolimus. Optimal sequencing and combination strategies are under investigation to improve patient outcomes.
Area of Science:
- Oncology
- Pharmacology
Background:
- Metastatic kidney cancer treatment has evolved significantly with new targeted therapies.
- International guidelines are updated, but key questions remain regarding optimal treatment sequencing and combinations.
Purpose of the Study:
- To review recent studies on targeted therapies for metastatic kidney cancer, focusing on data presented at ASCO 2007 and 2008.
- To highlight ongoing research addressing critical questions in treatment optimization.
Main Methods:
- Review of recent clinical studies and congress presentations (ASCO 2007, 2008).
- Discussion of ongoing clinical trials investigating treatment sequencing, combinations, and efficacy in specific settings.
Main Results:
- Demonstrated efficacy of several targeted agents including sunitinib, sorafenib, temsirolimus, bevacizumab with interferon, and everolimus.
- Emerging data on the tolerability and efficacy of combined targeted therapies.
Conclusions:
- The optimal sequencing of targeted therapies for metastatic kidney cancer requires further investigation.
- Ongoing studies aim to optimize treatment through exploring combinations, different histological subtypes, and neoadjuvant/adjuvant settings.
More Related Videos
15:04Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation
Published on: January 19, 2019
08:57Sample Extraction and Simultaneous Chromatographic Quantitation of Doxorubicin and Mitomycin C Following Drug Combination Delivery in Nanoparticles to Tumor-bearing Mice
Published on: October 5, 2017
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
01:24Modified-Release Drug Delivery Systems: Site-Targeted
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...